1. AstraZeneca gets FDA OK for Imfinzi in small-cell lung cancer— Regeneron and Sanofi treat first person outside US in coronavirus drug trial — FDA accepts Roche's NDA for Xofluza to treat flu in children — See more on our front page news Stay updated with the latest pharma-related coronavirus news on our new page
    Dismiss Notice
  2. Think you have witnessed fraud?Ask a Whistleblower Attorney -- a chance to discuss whistleblower-related legal issues with practicing whistleblower attorneys.
    Dismiss Notice

Be careful if you join Millennium/Takeda

Discussion in 'Millennium/Takeda Oncology Company' started by Anonymous, Jul 31, 2013 at 8:40 PM.

Tags: Add Tags
  1. Anonymous

    Anonymous Guest

    In spite of what you hear, this place is horrible. Takeda is eliminating most of the bonuses and it is very political and many in senior management are clueless. This company has never produced a drug that is marketed having in-licensed Velcade, Mepact, and Adcetris from others. TAK-700 just failed and 9708 is too late and if approved in 2 years will be hard to overcome the data from Celgene and Onyx.
     

  2. Anonymous

    Anonymous Guest

    Have to agree that most in upper management are clueless.